Comparative analysis of survivin expression in untreated and relapsed canine lymphoma

Robert B Rebhun, S. E. Lana, E. J. Ehrhart, J. B. Charles, D. H. Thamm

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Survivin, a member of the inhibitor of apoptosis protein family, has a dual role in tumor cell proliferative and antiapoptotic pathways. Survivin expression has been shown to be a negative prognostic factor in several cancers of humans, including B-cell non-Hodgkin's lymphoma. Hypotheses: High survivin expression will be a negative prognostic factor in dogs with lymphoma (LSA) treated with chemotherapy. In addition, survivin expression will be upregulated in relapsed canine LSA when compared with patient-matched, pretreatment biopsies. Animals: Thirty-one client-owned dogs with stage IIIa or IVa LSA. Methods: Retrospective evaluation of survivin immunoreactivity was performed on pretreatment lymph node biopsies and patient-matched samples obtained from dogs at relapse after being treated with an abbreviated CHOP-based protocol. Results: In this population of dogs presenting with stage IIIa or IVa B-cell LSA, those dogs that had high survivin immunoreactivity scores had a significantly (P < .01, hazard ratio = 0.30) shorter median disease-free interval than did dogs with low survivin immunoreactivity scores (171 days versus 321 days, respectively). Survivin immunoreactivity was not significantly different in relapsed canine LSA when compared with patient-matched, pretreatment biopsies. Conclusions and Clinical Importance: Survivin expression is a negative prognostic factor that can predict early treatment failure of dogs that present with stage IIIa or IVa, B-cell LSA when treated with a CHOP-based protocol.

Original languageEnglish (US)
Pages (from-to)989-995
Number of pages7
JournalJournal of Veterinary Internal Medicine
Volume22
Issue number4
DOIs
StatePublished - Jul 2008
Externally publishedYes

Fingerprint

lymphoma
Canidae
Lymphoma
Dogs
dogs
B-lymphocytes
biopsy
Biopsy
pretreatment
B-Lymphocytes
Inhibitor of Apoptosis Proteins
B-Cell Lymphoma
non-Hodgkin lymphoma
Treatment Failure
Non-Hodgkin's Lymphoma
relapse
Neoplasms
Lymph Nodes
drug therapy
lymph nodes

Keywords

  • Apoptosis
  • Dogs
  • IAP
  • Lymphosarcoma
  • Prognosis

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Comparative analysis of survivin expression in untreated and relapsed canine lymphoma. / Rebhun, Robert B; Lana, S. E.; Ehrhart, E. J.; Charles, J. B.; Thamm, D. H.

In: Journal of Veterinary Internal Medicine, Vol. 22, No. 4, 07.2008, p. 989-995.

Research output: Contribution to journalArticle

Rebhun, Robert B ; Lana, S. E. ; Ehrhart, E. J. ; Charles, J. B. ; Thamm, D. H. / Comparative analysis of survivin expression in untreated and relapsed canine lymphoma. In: Journal of Veterinary Internal Medicine. 2008 ; Vol. 22, No. 4. pp. 989-995.
@article{32a54ba10ed241c1ae979b3a498f16f2,
title = "Comparative analysis of survivin expression in untreated and relapsed canine lymphoma",
abstract = "Background: Survivin, a member of the inhibitor of apoptosis protein family, has a dual role in tumor cell proliferative and antiapoptotic pathways. Survivin expression has been shown to be a negative prognostic factor in several cancers of humans, including B-cell non-Hodgkin's lymphoma. Hypotheses: High survivin expression will be a negative prognostic factor in dogs with lymphoma (LSA) treated with chemotherapy. In addition, survivin expression will be upregulated in relapsed canine LSA when compared with patient-matched, pretreatment biopsies. Animals: Thirty-one client-owned dogs with stage IIIa or IVa LSA. Methods: Retrospective evaluation of survivin immunoreactivity was performed on pretreatment lymph node biopsies and patient-matched samples obtained from dogs at relapse after being treated with an abbreviated CHOP-based protocol. Results: In this population of dogs presenting with stage IIIa or IVa B-cell LSA, those dogs that had high survivin immunoreactivity scores had a significantly (P < .01, hazard ratio = 0.30) shorter median disease-free interval than did dogs with low survivin immunoreactivity scores (171 days versus 321 days, respectively). Survivin immunoreactivity was not significantly different in relapsed canine LSA when compared with patient-matched, pretreatment biopsies. Conclusions and Clinical Importance: Survivin expression is a negative prognostic factor that can predict early treatment failure of dogs that present with stage IIIa or IVa, B-cell LSA when treated with a CHOP-based protocol.",
keywords = "Apoptosis, Dogs, IAP, Lymphosarcoma, Prognosis",
author = "Rebhun, {Robert B} and Lana, {S. E.} and Ehrhart, {E. J.} and Charles, {J. B.} and Thamm, {D. H.}",
year = "2008",
month = "7",
doi = "10.1111/j.1939-1676.2008.0143.x",
language = "English (US)",
volume = "22",
pages = "989--995",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Comparative analysis of survivin expression in untreated and relapsed canine lymphoma

AU - Rebhun, Robert B

AU - Lana, S. E.

AU - Ehrhart, E. J.

AU - Charles, J. B.

AU - Thamm, D. H.

PY - 2008/7

Y1 - 2008/7

N2 - Background: Survivin, a member of the inhibitor of apoptosis protein family, has a dual role in tumor cell proliferative and antiapoptotic pathways. Survivin expression has been shown to be a negative prognostic factor in several cancers of humans, including B-cell non-Hodgkin's lymphoma. Hypotheses: High survivin expression will be a negative prognostic factor in dogs with lymphoma (LSA) treated with chemotherapy. In addition, survivin expression will be upregulated in relapsed canine LSA when compared with patient-matched, pretreatment biopsies. Animals: Thirty-one client-owned dogs with stage IIIa or IVa LSA. Methods: Retrospective evaluation of survivin immunoreactivity was performed on pretreatment lymph node biopsies and patient-matched samples obtained from dogs at relapse after being treated with an abbreviated CHOP-based protocol. Results: In this population of dogs presenting with stage IIIa or IVa B-cell LSA, those dogs that had high survivin immunoreactivity scores had a significantly (P < .01, hazard ratio = 0.30) shorter median disease-free interval than did dogs with low survivin immunoreactivity scores (171 days versus 321 days, respectively). Survivin immunoreactivity was not significantly different in relapsed canine LSA when compared with patient-matched, pretreatment biopsies. Conclusions and Clinical Importance: Survivin expression is a negative prognostic factor that can predict early treatment failure of dogs that present with stage IIIa or IVa, B-cell LSA when treated with a CHOP-based protocol.

AB - Background: Survivin, a member of the inhibitor of apoptosis protein family, has a dual role in tumor cell proliferative and antiapoptotic pathways. Survivin expression has been shown to be a negative prognostic factor in several cancers of humans, including B-cell non-Hodgkin's lymphoma. Hypotheses: High survivin expression will be a negative prognostic factor in dogs with lymphoma (LSA) treated with chemotherapy. In addition, survivin expression will be upregulated in relapsed canine LSA when compared with patient-matched, pretreatment biopsies. Animals: Thirty-one client-owned dogs with stage IIIa or IVa LSA. Methods: Retrospective evaluation of survivin immunoreactivity was performed on pretreatment lymph node biopsies and patient-matched samples obtained from dogs at relapse after being treated with an abbreviated CHOP-based protocol. Results: In this population of dogs presenting with stage IIIa or IVa B-cell LSA, those dogs that had high survivin immunoreactivity scores had a significantly (P < .01, hazard ratio = 0.30) shorter median disease-free interval than did dogs with low survivin immunoreactivity scores (171 days versus 321 days, respectively). Survivin immunoreactivity was not significantly different in relapsed canine LSA when compared with patient-matched, pretreatment biopsies. Conclusions and Clinical Importance: Survivin expression is a negative prognostic factor that can predict early treatment failure of dogs that present with stage IIIa or IVa, B-cell LSA when treated with a CHOP-based protocol.

KW - Apoptosis

KW - Dogs

KW - IAP

KW - Lymphosarcoma

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=47849118398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47849118398&partnerID=8YFLogxK

U2 - 10.1111/j.1939-1676.2008.0143.x

DO - 10.1111/j.1939-1676.2008.0143.x

M3 - Article

C2 - 18647159

AN - SCOPUS:47849118398

VL - 22

SP - 989

EP - 995

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 4

ER -